Disruptive genomic technologies hold great promise to dramatically improve patient care and lower costs, but they also face unique challenges related to market access and adoption. John Dobak, M.D., CEO of DermTech, will share some of the unique challenges and opportunities his company has faced bringing to market their breakthrough non-invasive skin genomics platform and product for the early detection of melanoma.
DermTech is the leader of a new category of medicine, precision dermatology. Our mission is to transform the practice of dermatology through more accurate diagnosis and treatment, and the elimination of unnecessary surgery, leading to improved patient care and lower costs. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. We market and develop products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. For additional information visit: dermtech.com.